Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin

Access
info:eu-repo/semantics/closedAccessDate
2015Author
Amin, AlpeshKeshishian, A
Xie, L
Başer, Onur
Price, K
Vo, L
Singh, P
Bruno, A
Mardekian, J
Tan, W
Singhal, S
Patel, C
Odell, K
Trocio J.
Metadata
Show full item recordCitation
Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. (November 7-11, 2015). Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. American Heart Association (AHA) Scientific Sessions 2015. Orlando, FL.Abstract
...